Summary
This Form 8-K filing from Bristol-Myers Squibb (BMY), dated March 4, 2005, primarily details compensation decisions made by the Compensation and Management Development Committee for the company's Named Executive Officers. Key actions include the authorization of 2004 annual cash bonus awards, with CEO Peter R. Dolan receiving $2,125,000, and the approval of base salaries for the upcoming fiscal year, effective April 1, 2005, with most executive salaries remaining unchanged from the previous year, except for Dr. Elliott Sigal whose salary reflects a promotion. Furthermore, the filing announces the grant of performance share units for the 2005-2007 period. These units are tied to achieving cumulative earnings per share and sales goals, with potential payouts ranging from zero to 253% of target, and further adjusted by total shareholder return relative to peers. The company emphasizes that these compensation decisions are structured to comply with Section 162(m) of the Internal Revenue Code, aiming for tax deductibility of cash compensation paid to officers.
Key Highlights
- 1BMY's Compensation Committee authorized 2004 annual cash bonus awards for Named Executive Officers, with CEO Peter R. Dolan receiving $2.125 million.
- 2The 2004 bonuses were based on company pre-tax earnings targets and individual executive performance.
- 3Base salaries for Named Executive Officers were approved, effective April 1, 2005. Most remained at their 2004 levels, with an adjustment for Dr. Elliott Sigal due to a promotion.
- 4The company granted performance share units for the 2005-2007 period to Named Executive Officers.
- 5Payouts for performance share units are contingent on achieving cumulative EPS and sales goals over the three-year period.
- 6The maximum payout for performance share units can reach 253% of the target, with a minimum of zero.
- 7The compensation structure is designed to qualify for tax deductibility under Section 162(m) of the Internal Revenue Code.